Refanezumab (Synonyms: GSK249320)

Cat. No.: HY-P99403: FAQs
Data Sheet

Molarity Calculator

Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke.

For research use only. We do not sell to patients.

Refanezumab Chemical Structure

CAS No. : 1233953-61-1

Size		Stock
1 mg		Get quote	Estimated Time of Arrival: December 31
5 mg		Get quote	Estimated Time of Arrival: December 31

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vivo

Refanezumab (GSK249320; 10 mg/kg; IV; starting 24 hours post-stroke and continuing weekly for 6 more doses) shows larger increases in neuroscore and staircase test. Refanezumab by intravenous penetrates the lesion site and is associated with a small effect on functional outcomes when initiated 24 hours post-stroke^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague Dawley rats (weight 361g)^[1]
Dosage:	10 mg/kg
Administration:	IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses
Result:	Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit.

Clinical Trial

CAS No.

1233953-61-1

SMILES

[Refanezumab]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Diana Cash, et al. GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke. J Neurol Exp Neurosci. 2016;2(2):28-33. Epub 2016 Nov 21. [Content Brief]

[2]. B Abila, et al. First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9. [Content Brief]

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Refanezumab1233953-61-1GSK249320GSK 249320GSK-249320OthersIgG1-typehumanizedmonoclonal antibodymyelin-associated glycoproteinMAGaxonal regenerationblood-brain barrierBBBstrokeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks